Research and Development Expenses Breakdown: Rhythm Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.

R&D Spending Trends in Biopharmaceuticals: A Decade of Growth

__timestampBioCryst Pharmaceuticals, Inc.Rhythm Pharmaceuticals, Inc.
Wednesday, January 1, 2014517960005280000
Thursday, January 1, 2015727580007148000
Friday, January 1, 20166100800019594000
Sunday, January 1, 20176696200022894000
Monday, January 1, 20188488800050337000
Tuesday, January 1, 2019107068000109450000
Wednesday, January 1, 202012296400090450000
Friday, January 1, 2021208808000104128000
Saturday, January 1, 2022253297000108630000
Sunday, January 1, 2023216566000134951000
Loading chart...

Unleashing insights

A Decade of Innovation: R&D Spending in Biopharmaceuticals

In the ever-evolving landscape of biopharmaceuticals, research and development (R&D) expenses are a critical indicator of a company's commitment to innovation. Over the past decade, BioCryst Pharmaceuticals, Inc. and Rhythm Pharmaceuticals, Inc. have demonstrated significant investment in R&D, reflecting their dedication to advancing medical science.

BioCryst Pharmaceuticals, Inc.

BioCryst has consistently increased its R&D spending, peaking in 2022 with a 390% rise from 2014. This surge underscores their strategic focus on developing groundbreaking treatments.

Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, while starting with modest R&D expenses in 2014, has shown a remarkable growth trajectory, with a 2,455% increase by 2023. This highlights their aggressive pursuit of innovative solutions in the pharmaceutical sector.

Both companies exemplify the dynamic nature of the biopharmaceutical industry, where substantial R&D investments are pivotal for future breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025